Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

AKR1C3

2 abstracts

Abstract
Safety, tolerability, pharmacokinetics and clinical activity of AST-3424, an AKR1C3-activated bis-alkylating moiety prodrug, in subjects with advanced solid tumors in China: A phase I dose-escalation study.
Org: Ascentawits Pharmaceuticals, Ltd, Shenzhen, China, Ascentawits Pharmaceuticals, Ltd, Foster City, CA, Ascentawits Pharmaceuticals Ltd, Shenzhen, China,
Abstract
A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC).
Org: UC Davis Department of Internal Medicine, UC Davis Medical Center, Department of Medicine, Brigham and Women’s Hospital,